Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist

NCT02971722 is registered in ClinicalTrials.gov with Beijing Dongfang Biotech Co., Ltd. as lead sponsor.

NCT NCT02971722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02971722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist
Lead sponsor
Beijing Dongfang Biotech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2016
Completion date
March 31, 2018
Enrollment
26 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy